Previous Page
40
nanotimes
Companies Facts
are being applied to accelerating and completing both VivaGel®
Bacterial Vaginosis Phase 3 pro-
grams (Treatment, and Prevention of Recurrence) supporting an NDA filing and commercial licence, as well as advancing the Company’s drug delivery and agrochemical programs.
Furthermore, Starpharma Holdings (ASX: SPL, OTCQX: SPHRY) released animal data which de- monstrated that its dendrimer-docetaxel formula- tion applying Starpharma’s dendrimer technolo- gy to the leading chemotherapy drug docetaxel was significantly more efficacious than docetaxel (Taxotere®
a leading chemotherapy drug used to treat a wide range of solid tumours including breast, lung and prostate. It is marketed by Sanofi Aventis as Taxo- tere®
12-01 :: January 2012
cost-efficient hydrogenation with superior yield when compared to conventional methods.
) in a breast cancer model. Docetaxel is and generated sales in excess of US$3 billion
in 2010. Starpharma conducted the latest study, a breast cancer xenograft in mice, as part of its drug delivery program for docetaxel - having already demonstrated a marked improvement in the water solubility of docetaxel with its dendrimer formulati- on. This study was designed to assess the efficacy of Starpharma’s dendrimer-docetaxel formulations in treating cancer.
http://www.starpharma.com H -Cube® by ThalesNano is a continuous-flow hydrogenation reactor. A revolutionary bench-
top standalone hydrogenation reactor, uniquely combining continuous-flow microchemistry with endogenous on-demand hydrogen generation and a disposable catalyst cartridge system. It allows fast and
T http://www.youtube.com/watch?v=bdbLVQqaKd4
egal Corporation (NASDAQ: TGAL) has awarded patents to multiple bidders for three of the four
bid lots of Tegal’s NLD Patent Portfolio recently offered for sale for an aggregate consideration of approximately $4M. To date, approximately $3.6M has been received. Tegal sold over 30 patents from the NLD portfolio – which includes more than 35 U.S. and international patents in the areas of pulsed- chemical vapor deposition (CVD), plasma-enhanced atomic-layer deposition (ALD) and NLD.
In March 2010, Tegal sold its legacy thin-film etch and physical vapor deposition (PVD) product lines to OEM Group, Inc. of Gilbert AZ, and in February of this year, sold its deep reactive ion etch (DRIE) assets to SPTS of Newport, Wales, UK.